↓ Skip to main content

The position of strontium ranelate in today’s management of osteoporosis

Overview of attention for article published in Osteoporosis International, April 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
83 Dimensions

Readers on

mendeley
70 Mendeley
Title
The position of strontium ranelate in today’s management of osteoporosis
Published in
Osteoporosis International, April 2015
DOI 10.1007/s00198-015-3109-y
Pubmed ID
Authors

J.-Y. Reginster, M.-L. Brandi, J. Cannata-Andía, C. Cooper, B. Cortet, J.-M. Feron, H. Genant, S. Palacios, J. D. Ringe, R. Rizzoli

Abstract

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving, especially in patient with severe osteoporosis or patients who cannot take certain osteoporosis medications due to issues of contraindications or tolerability. Following recent regulatory changes, strontium ranelate is now indicated in patients with severe osteoporosis for whom treatment with other osteoporosis treatments is not possible, and without contraindications including uncontrolled hypertension, established, current or past history of ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. We review here today's evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy of strontium ranelate is maintained in patients with severe osteoporosis without contraindications and also demonstrated how the new target population mitigates risk. Strontium ranelate is therefore an important alternative in today's management of osteoporosis, with a positive benefit-risk balance, provided that the revised indication and contraindications are followed and cardiovascular risk is monitored. The bone community should be reassured that there remain viable alternatives in patients in whom treatment with other agents is not possible and protection against the debilitating effects of fracture is still feasible in patients with severe osteoporosis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 70 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 16%
Student > Master 9 13%
Researcher 8 11%
Student > Ph. D. Student 6 9%
Other 5 7%
Other 14 20%
Unknown 17 24%
Readers by discipline Count As %
Medicine and Dentistry 18 26%
Biochemistry, Genetics and Molecular Biology 7 10%
Chemistry 6 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Agricultural and Biological Sciences 3 4%
Other 9 13%
Unknown 23 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2015.
All research outputs
#14,807,732
of 22,799,071 outputs
Outputs from Osteoporosis International
#2,215
of 3,608 outputs
Outputs of similar age
#148,450
of 264,369 outputs
Outputs of similar age from Osteoporosis International
#50
of 91 outputs
Altmetric has tracked 22,799,071 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,608 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,369 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.